Detalhe da pesquisa
1.
Efficacy and safety of sovleplenib (HMPL-523) in adult patients with chronic primary immune thrombocytopenia in China (ESLIM-01): a randomised, double-blind, placebo-controlled, phase 3 study.
Lancet Haematol;
2024 Jun 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-38885672
2.
Switching from eltrombopag to hetrombopag in patients with primary immune thrombocytopenia: a post-hoc analysis of a multicenter, randomized phase III trial.
Ann Hematol;
2024 Jun 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-38842566
3.
Bispecific antibodies targeting CD20xCD3 in immunotherapy for adult B-cell lymphoma: insights from the 65th American Society of Hematology 2023 annual meeting.
Expert Opin Biol Ther;
24(5): 321-326, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38717336
4.
A novel anti-LAG-3/TIGIT bispecific antibody exhibits potent anti-tumor efficacy in mouse models as monotherapy or in combination with PD-1 antibody.
Sci Rep;
14(1): 10661, 2024 05 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-38724599
5.
Venetoclax combined chemotherapy versus chemotherapy alone for acute myeloid leukemia: a systematic review and meta-analysis.
Front Oncol;
14: 1361988, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38595818
6.
Monitoring ROS Responsive Fe3O4-based Nanoparticle Mediated Ferroptosis and Immunotherapy via 129Xe MRI.
Angew Chem Int Ed Engl;
63(22): e202403771, 2024 May 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-38551448
7.
Cysteine- and glycine-rich protein 1 predicts prognosis and therapy response in patients with acute myeloid leukemia.
Clin Exp Med;
24(1): 57, 2024 Mar 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-38546813
8.
Bispecific antibodies in immunotherapy for adult acute leukemia: latest updates from the 65th American Society of Hematology 2023 Annual Meeting.
Expert Opin Biol Ther;
24(4): 221-223, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38506624
9.
Jellyfish-inspired smart tetraphenylethene lipids with unique AIE fluorescence, thermal response, and cell membrane interaction.
J Mater Chem B;
12(9): 2373-2383, 2024 Feb 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-38349037
10.
Efficacy, safety, and survival findings after long-term follow-up of ZGJAK002: A phase 2 study comparing jaktinib at 100 mg twice daily (BID) and 200 mg once daily (QD) in patients with myelofibrosis.
Am J Hematol;
99(4): 774-779, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38343062
11.
Targeting TIGIT for cancer immunotherapy: recent advances and future directions.
Biomark Res;
12(1): 7, 2024 Jan 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-38229100
12.
Targeting CD24/Siglec-10 signal pathway for cancer immunotherapy: recent advances and future directions.
Cancer Immunol Immunother;
73(2): 31, 2024 Jan 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-38279998
13.
Allogeneic CAR-T cells with of HLA-A/B and TRAC disruption exhibit promising antitumor capacity against B cell malignancies.
Cancer Immunol Immunother;
73(1): 13, 2024 Jan 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-38231412
14.
Current situation and development of hematopoietic cell transplantation centers: A nationwide survey in China.
Chin Med J (Engl);
2024 Jan 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-38251709
15.
Oligosecretory Waldenström macroglobulinemia exhibits excellent treatment response and outcomes.
Haematologica;
109(2): 666-670, 2024 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37706332
16.
Unbiased Single-Cell Sequencing of Hematopoietic and Immune Cells from Aplastic Anemia Reveals the Contributors of Hematopoiesis Failure and Dysfunctional Immune Regulation.
Adv Sci (Weinh);
11(10): e2304539, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38145351
17.
Targeted single-cell RNA sequencing analysis reveals metabolic reprogramming and the ferroptosis-resistant state in hematologic malignancies.
Cell Biochem Funct;
41(8): 1343-1356, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37823726
18.
TBAF-Mediated [3+1] Cycloaddition of Difluorocarbene to Access gem-Difluorinated 1,2-Diazetidine Analogues as Potent Anticancer Agents.
Org Lett;
25(41): 7567-7572, 2023 10 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-37815920
19.
Bispecific antibodies as monotherapy or in combinations for hematological malignancies: latest updates from the EHA 2023 annual meeting.
Expert Opin Biol Ther;
23(12): 1193-1195, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37852928
20.
IMM47, a humanized monoclonal antibody that targets CD24, exhibits exceptional anti-tumor efficacy by blocking the CD24/Siglec-10 interaction and can be used as monotherapy or in combination with anti-PD1 antibodies for cancer immunotherapy.
Antib Ther;
6(4): 240-252, 2023 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-37846296